InvestorsHub Logo
Followers 19
Posts 817
Boards Moderated 0
Alias Born 12/12/2016

Re: plexrec post# 116645

Tuesday, 08/22/2017 5:56:30 PM

Tuesday, August 22, 2017 5:56:30 PM

Post# of 457448
The Anavex train indeed Plex. Looks like they could be on track as well for Parkinson's trial readout in advance of Dr Francardo's presentation in May 2018 regarding a2-73 Parkinson's results.

Found her statements below to be fairly definitive and unambiguous re her testing to date. It seems the MJFF grant funds are being put to good use here.

GLTAL

Excerpted below from Dr Francardo [who is an independent researcher with grant funds from the Michael J. Foundation and has been studying the sigma-1 receptor for many years and publishing on the topic since at least 2011 (thanks again for pointing that out OFP)]:

"Using the same animal model of PD as in our previous study (i.e. intrastriatal 6-OHDA mouse model), we investigated the potential neurorestorative effects of ANAVEX 2-73, a compound with activity at both Sigma-1 and muscarinic receptors that is currently being tested in people affected by Alzheimer´s disease. Our results reveal that ANAVEX 2-73 is able to ameliorate parkinsonian motor symptoms in tests assessing spontaneous rotational activity and forelimb use asymmetry, and exerts neuroprotective/neurorestorative effects on the nigrostriatal dopamine system."

https://www.michaeljfox.org/foundation/researchers.php?id=1841
Veronica Francardo, PhD
Assistant Professor, Department of Experimental Medical Science BMC F11 at Lund University
Location: Lund, Sweden

Veronica Francardo received her undergraduate training at the University of Trieste, Italy, where she graduated in Medical Biotechnologies. Since 2007, Veronica is a researcher at Lund University, Sweden, where she obtained her PhD degree in Neurobiology under the supervision of Prof Angela Cenci-Nilsson. Veronica Francardo is currently Assistant Professor in the group of Prof. Angela Cenci-Nilsson and carries out pre-clinical research on animal models of Parkinson’s disease and post-mortem human brain tissue. The main interest of her work is to test and develop potential new therapies for Parkinson’s disease and related disorders."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News